WebNov 15, 2024 · In recent months, Myovant Sciences ( NYSE: MYOV) has evolved from a clinical development company to a successful commercial company. Currently, … WebApr 11, 2024 · The company's 50 day moving average price is $26.96 and its two-hundred day moving average price is $26.25. Myovant Sciences (NYSE:MYOV - Get Rating) last posted its earnings results on Thursday, January 26th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by …
MUSE Awards Integrated Marketing Campaign Myovant Sciences
WebMar 10, 2024 · Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, … WebOct 25, 2024 · Myovant Sciences focused on a single API and had a single shareholder own over half of its shares. While that led to an acquisition, it also limited the company's pre- and post-takeover valuation. freya shapewear
Myovant Sciences LinkedIn
WebMar 10, 2024 · Sumitovant has acquired all outstanding shares of Myovant not already owned by Sumitovant in an all-cash deal with a total transaction value of approximately $1.7 billion. With the completion of the acquisition, Myovant will be delisted from the New York Stock Exchange, and its shares will no longer be publicly traded. WebMyovant Sciences is a biotech company that develops new treatments for infertility in women and prostate cancer in men. Acquired by Sumitovant Brisbane, California, United States 501-1000 Post-IPO Debt Public myovant.com 14,525 Highlights Stock Symbol NYSE:MYOV Total Funding Amount $340M Contacts 326 Employee Profiles 5 Investors 3 WebStay connected and stay well with MyNovant. Access your Novant MyChart account for paying bills, scheduling appointments and more. father of civil aviation